Abstract Library

#1918 Case Study: Immunotherapy in a Young Adult with Atypical Neuroendocrine Tumour

Introduction: Use of immunotherapy PD-1 antibody has emerged as a novel therapeutic option for treating multiple solid tumors. In the setting of neuroendocrine tumors (NETs), little is known. Currently, trials are underway investigating its use in high-grade NETs, but outcomes remain to be seen

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kavan P

Authors: Stavrides-Eid M, Soo Rho Y, Barrera I, Kavan P,

Keywords: thymic neuroendocrine tumour, pembrolizumab, atypical carcinoid, NETs,

#1467 iFiT: An Integrative Bioinformatics Platform for Biomarker and Target Discovery. A Case Study in Neuroendocrine Tumors

Introduction: iFiT (Ipsen Focused-on-new bIological enTities and biomarkers) is a Bioinformatics platform integrating systems biology functionalities together with semantic & logic-based artificial intelligence within a high-scale computing environment.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Tourlet S

Authors: Tourlet S, Scaerou F, Martin A, Thiagalingam A, Paty I,

Keywords: Targets iFiT,

#855 Extrapulmonary Small Cell Neuroendocrine Carcinoma of the Colon in an 18-Year-Old Girl

Introduction: Extrapulmonary small cell carcinoma (EPSCC) is a very rare aggressive malignant tumor typical for older age. Prognosis of EPSCC remains very poor, with three years OS 38% and five years OS less than 13%. The median survival for GI localised EPSCC is only five months. Initial extent of disease is the most sensitive prognostic factor.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Bajciova V

Authors: Bajciova V, Kren L, Oltova A,

Keywords: colon EPSCC, young age,

#699 Ethanol Ablation in an 81-Year-Old Patient with Pancreatic Neuroendocrine Tumor (Islet Cell Tumor) and Severe Hypoglycemia – A Case Study.

Introduction: The key clinical problem in patients with islet cell tumors are persistent hypoglycemia episodes, which are particularly dangerous in the elderly since neuroglycopenia may be the cause of stroke.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Andrysiak-Mamos E, Starzyńska T, Białek A, Sowińska-Przepiera E, Kazmierczyk-Puchalska A,

Keywords: ethanol ablation, neuroendocrine tumor, islet cell tumor,

#154 Long-term disease stabilization in a patient with advanced pancreatic neuroendocrine tumor treated with combined everolimus and octreotide LAR after prior failure of cytotoxic therapy

Introduction: Targeting of multiple pathways has become an important strategy for improved tumor control in metastatic neuroendocrine tumors (NETs). Among these targets is the mammalian target of rapamycin (mTOR), a central regulator of cell growth, proliferation, and apoptosis, which is blocked by everolimus, an oral inhibitor of mTOR that has shown efficacy in patients with metastatic pancreatic NETs. Recent evidence has suggested that suppression of insulin-like growth factor-1 receptor (IGF-1R) secretion with octreotide therapy, along with concurrent inhibition of mTOR by everolimus, may improve tumor control synergistically by preventing feedback activation of the PI3K/Akt/mTOR pathway.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Teulé Vega A, Ochoa M, Villabona C, Cuadra C, Salazar Soler R,

Keywords: pancreatic neuroendocrine tumor, everolimus, octreotide LAR, case study,